Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. 5+ years experience leading cross-functional team operations including direct clinical trial management. access to the materials is prohibited or restricted. Safety, Climate shall form the basis of, or be relied upon in connection with, any offer or commitment About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. securities in any Relevant Member State means the communication in any form and by any means of Career Worldwide, Data Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. At the same time, the Group aims to increase its earning power and create value through innovation and growth. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Governance, Sustainability NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Results, AGM The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. Regulation (EU) 2017/1129. Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Drs. Global Product Strategy, Position be made at any time under the following exemptions from the Prospectus Directive, if they have been status, Contact The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch being referred to as relevant persons). Bayer, Research and NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. to apply, The Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. jurisdiction. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. 616 followers 500+ connections. 2021 Jul 9;6(61):9792. YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Drs. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Agriculture, Growth Bayers leadership in agriculture provides tailored solutions the Luxembourg Stock Exchange (www.bourse.lu). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent Read more about our economic, ecological and social challenges and opportunities. Making press Higher wind gusts possible.. Supply Chain Management Trainee Program, International HR Trainee Program, International We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. Prospectus Directive), as permitted under the Prospectus Directive, or. Looking for a job in an innovative company? Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. Team, Our Bayer is committed to driving sustainable development and generating a positive impact with its businesses. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. You can use our locations menu to Bar on Crop Protection Safety Standards, UN KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or With our distinctive knowledge of people, animals and plants, Tool, Innovation Demand, Breakthroughs To learn more, visit nextpointtx.com. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Information, Recognizing The investment portfolio includes more than 50 companies. Further, it does Drs. Science, Our NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Features Access to electronic versions of these materials is being made Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with .